MGMT promoter methylation is a common feature of IDH1/2 mutant/G-CIMP positive glioma, however, is less prevalent in G-CIMP negative tumors, such as primary glioblastoma, where MGMT methylation occurs in approximately 40% of cases (22–24). This evidence concerns the gene MGMT and central nervous system cancer.